Contineum Therapeutics, Inc. financial data

Symbol
CTNM on Nasdaq
Industry
Pharmaceutical Preparations
Location
10578 Science Center Drive, Suite 200, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19M shares
Weighted Average Number of Shares Outstanding, Basic 23.4M shares +919%
Weighted Average Number of Shares Outstanding, Diluted 23.4M shares +565%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 7.9M USD -16.5%
General and Administrative Expense 3.04M USD +89.8%
Operating Income (Loss) -10.9M USD -128%
Nonoperating Income (Expense) 1.94M USD -42.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.01M USD -121%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -9.01M USD -122%
Earnings Per Share, Basic -0.39 USD/shares -115%
Earnings Per Share, Diluted -0.39 USD/shares -146%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.2M USD
Marketable Securities, Current 141M USD
Cash, Cash Equivalents, and Short-term Investments 219M USD
Assets, Current 220M USD
Property, Plant and Equipment, Net 801K USD
Operating Lease, Right-of-Use Asset 231K USD
Other Assets, Noncurrent 3K USD
Assets 221M USD
Accounts Payable, Current 734K USD
Employee-related Liabilities, Current 1.4M USD
Accrued Liabilities, Current 2.52M USD
Liabilities, Current 3.74M USD
Operating Lease, Liability, Noncurrent 113K USD
Other Liabilities, Noncurrent 0 USD
Liabilities 3.85M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -127K USD
Retained Earnings (Accumulated Deficit) -92.6M USD
Stockholders' Equity Attributable to Parent 218M USD
Liabilities and Equity 221M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.08M USD -122%
Operating Lease, Liability, Current 484K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 310M USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares